25I-NBOH

Discovery

The structural scaffold for 25I-NBOH was established in 2006, when researchers demonstrated that attaching an N-benzyl group to 2C-class phenethylamines could increase serotonin receptor binding by up to 300-fold.^[1] The NBOMe series reached research chemical markets around 2010–2011; the NBOH series followed shortly after. The precise date of 25I-NBOH's first synthesis has not been published.

Forensic identification and market presence

25I-NBOH was first confirmed in seized blotter papers from Brazil in 2017, with individual dose loads ranging from 300 to 1,000 µg.^[2] A key complication: the compound breaks down under standard forensic heat testing, causing it to be misidentified as 2C-I.^[2][5][6] It was likely present in earlier seizures but recorded under the wrong name.

Scheduling and scientific characterization

Regulatory action has proceeded jurisdiction by jurisdiction, generally trailing behind the more documented 25I-NBOMe. Louisiana scheduled 25I-NBOH in June 2013,^[7] Sweden in August 2015,^[7] and Brazil around the same period.^[2] Product reliability remains poor — one analyzed sample sold as "25I-NBOH" contained entirely different substances, including a stimulant.^[3]

Structural class

25I-NBOH belongs to the substituted phenethylamine family, specifically the 25x-NBOH series. Its parent compound is 2C-I, first documented by Alexander Shulgin.citation needed Adding a 2-hydroxybenzyl group to the amine nitrogen increases serotonin receptor binding affinity by up to 300-fold^[1] — a single structural change that converts a moderately potent compound into an extremely potent one.

Molecular properties

The 2,5-dimethoxy substitution pattern is essential for psychedelic activity — removing either methoxy group markedly reduces potency beyond what binding data alone would predict.^[8] The NBOH scaffold differs from the closely related NBOMe series by one functional group: a free hydroxyl instead of a methoxy, changing how the body metabolizes it and how it behaves under heat.^[9]

Mechanism of action

25I-NBOH is a potent full agonist at serotonin receptors, with functional potency comparable to LSD.^[10] It does not affect dopamine or norepinephrine reuptake — stimulant-like effects come entirely from serotonin activity.^[10] Research shows that serotonin's Gq signaling pathway is what correlates with psychedelic potential.^[11]

Pharmacokinetics

No human pharmacokinetic data have been published — bioavailability, peak timing, and half-life are unknown. The body processes 25I-NBOH primarily through the liver enzyme CYP2D6 — a different enzyme than the one used to clear 25I-NBOMe.^[9] People with non-functional CYP2D6 genes, and those taking antidepressants that block this enzyme, may experience substantially stronger and longer-lasting effects.^[9]

Where it acts

No human brain imaging data exist for 25I-NBOH. As a potent serotonin receptor agonist, it is expected to activate specific neurons in the prefrontal cortex — the primary cellular trigger for serotonergic psychedelic effects. Studies using a related compound show this creates a push-pull dynamic: sensory input is heightened while overall firing is suppressed, which may explain why heightened perception coexists with impaired executive function.^[12]

Theoretical frameworks

The leading framework holds that potent serotonin activation disrupts the brain's normal processing hierarchy, weakening its reliance on prior expectations and increasing neural flexibility.citation needed This produces the visual shifts, heightened sense of meaning, and boundary dissolution characteristic of psychedelics. Animal recordings during 25I-NBOH use show a distinctive slow brainwave pattern accompanying behavioral changes.^[13]

Toxicity

No lethal dose, therapeutic index, or systematic toxicology data have been published for 25I-NBOH. The acute toxicity profile is inferred from the structural analog 25I-NBOMe and the broader N-benzylphenethylamine class.inferred

Psychological risks

Acute psychological distress — panic and overwhelming fear — is documented in clinical cases involving related N-benzylphenethylamine compounds.^[17] Agitation, confusion, and excited delirium occur at high doses.^[15] Community reports describe perceptual or cognitive disturbances lasting 3–12 days after use.

Hallucinogen persisting perception disorder (hallucinogen-persisting perception disorder) is documented for serotonergic psychedelics as a class but has not been specifically reported for 25I-NBOH.citation needed People with personal or family histories of psychotic disorders or bipolar disorder face elevated risk of psychiatric destabilization.

Tolerance and dependence

25I-NBOH is not habit-forming. Tolerance builds rapidly after a single dose — the brain downregulates its serotonin receptors — with full reset estimated at approximately two weeks.inferred This rapid tolerance inherently limits compulsive use.

Cross-tolerance with LSD, psilocybin, mescaline, and other NBOH/NBOMe compounds is expected given the shared receptor mechanism. No physical dependence or withdrawal has been described for any NBOH compound.

Drug interactions

The primary risk is serotonin syndrome — dangerous overheating, muscle rigidity, and rapid heart rate. Combining 25I-NBOH with any drug that raises serotonin levels can trigger this: MAOIs, SSRIs, and SNRIs interact this way.safety citation needed Tramadol is classified as a dangerous interaction — it raises serotonin^[18] and independently lowers the seizure threshold.^[15]

A separate risk involves the liver enzyme CYP2D6, which the body uses to clear 25I-NBOH.^[9] Drugs that block this enzyme — including fluoxetine, paroxetine, and bupropion — can substantially increase drug levels. Fluoxetine and paroxetine carry double risk: they block CYP2D6 and raise serotonin simultaneously.

Contraindications

Severe heart conditions are an absolute contraindication. The N-benzylphenethylamine class raises heart rate, blood pressure, and constricts blood vessels^[15] — dangerous with coronary artery disease, uncontrolled high blood pressure, or recent stroke. Seizure disorders are also an absolute contraindication, as seizures are a documented complication of severe poisoning from this class.^[16][15]

Concurrent serotonergic medications — MAOIs, SSRIs, SNRIs, tramadol — are contraindicated due to serotonin syndrome risk. CYP2D6 poor metabolizer status is a relative contraindication, as non-functional CYP2D6 genes may substantially elevate and prolong effects.^[9] Personal or family history of psychotic or bipolar disorder is also a relative contraindication.citation needed

As of 2017, 25I-NBOH was not controlled under United Nations international drug conventions.^[2] National scheduling has followed on a jurisdiction-by-jurisdiction basis, generally trailing behind the more documented 25I-NBOMe.